Our pioneering SomaScan® assay is a game changer for your oncology research
The SomaScan assay is designed for sensitivity and specificity to detect low-abundant proteins, such as cytokines, to lead to your next breakthrough discovery.
The SomaScan® assay empowers discovery
Accelerate your biomarker discovery with sensitive detection of 7,000 proteins from a 55-μL sample.
Identify unique cancer-specific protein biomarkers for future diagnostic indicators.
Monitor proteins over time for markers indicative of disease progression/regression.
Reveal proteins that correlate with a cancer event for development of preventive measures.
Define protein signatures that correlate with specific subtypes for use in therapeutic development.
Also available: SomaScan® panels for targeted data
White paperCirculating protein biomarkers are a promising avenue for predicting patient response to cancer immunotherapiesCancer Immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. While offering a generally safer and more efficacious alternative to standard chemotherapy and radiotherapy, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events. An understanding of the molecular factors that contribute to clinical outcomes could enable improved selection of subject cohorts; therefore, identifying predictive biomarkers of immunotherapy response has become a growing focus of immuno-oncology research.
WebinarProteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatmentIn this 1-hour discussion, you will learn how large-scale proteomics can be leveraged for multiple applications in the field of oncology. The focus will be on 2 new avenues of oncology research. The first is using proteomic risk scores to monitor the cardiotoxic effects of anthracycline treatment and identify patients who may benefit from cardioprotective therapy. The other is developing blood-based protein tests for stratifying lung cancer susceptibility. From biomarker discovery to medicine application and the potential to inform and impact patients’ standard of care—there is a lot to learn and look forward to in oncology research using proteomics.